Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer

Published Date: 23 Aug 2024

Lazertinib plus amivantamab improved PFS by about 7 months versus single-agent osimertinib

Read Full News

Latest News

US to Loosen Marijuana Rules in Major Shift for $47 Billion Industry

The U.S. Department of Justice said on Thursday it would immediately loosen restrictions on some marijuana products and move quickly to reclassify the drug as less...

Low Income, Education Tied to Depression in Older Adults

Older adults with chronic disease who have less education, lower income, and no active jobs tend to experience symptoms of depression.

Why Encouragement May Not Improve Motivation in Depression

A meta-analysis identifies impaired effort-based decision making across psychiatric disorders, pointing to actionable targets for improving motivation and functional outcomes.

Brexpiprazole Safe, Effective in Early-Episode Schizophrenia

Brexpiprazole is linked to reduced symptoms, improved functioning, and greater response compared with placebo in patients with early-episode schizophrenia, new research shows.

Do Anatomy Atlases Reflect Social Inequalities?

Historical anatomical illustrations reflect social inequality and may require an ethical context to guide their continued use in clinical education and surgical reference.

Novel Psychedelic Promising on Resistant Depression

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Todays Updates

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

Todays Updates

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

Latest News

The U.S. Department of Justice said on Thursday it would immediately loosen restrictions on some marijuana products and move quickly to reclassify the drug as less...

Older adults with chronic disease who have less education, lower income, and no active jobs tend to experience symptoms of depression.

A meta-analysis identifies impaired effort-based decision making across psychiatric disorders, pointing to actionable targets for improving motivation and functional outcomes.

Brexpiprazole is linked to reduced symptoms, improved functioning, and greater response compared with placebo in patients with early-episode schizophrenia, new research shows.

Historical anatomical illustrations reflect social inequality and may require an ethical context to guide their continued use in clinical education and surgical reference.

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

News All Time

Making informed decisions and managing regret after prostate cancer treatment

A prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, you may be faced with multiple treatment options and asked to make a choice—surgery, radiation ...

Nasal therapeutic HPV vaccine could prevent cervical cancer

Cervical cancer, which affects the reproductive tract, is one of the most common cancers in women worldwide. It is primarily caused by human papillomavirus (HPV), a viral infection that spreads through sexual contact.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia

A new type of cancer cell that "warrants urgent investigation" has been discovered in childhood leukemia and could impact clinical care. Research into new or repurposed treatments that target this new cell type could give ...

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination. Her primary care physician had ruled out diabetes before finally ...

Doctors say lung cancer is still the deadliest cancer, but hope is growing

Lung cancer remains the leading cause of cancer death in the U.S., responsible for about 1 in 4, but major advances in screening, surgery and personalized treatment are helping more patients live longer.

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists—the class of drugs behind Ozempic, Wegovy and Mounjaro, for example—may do more than regulate ...

Best foot forward—chemo care should include podiatry, say researchers

Irreversible nerve damage to the lower limbs is a common side effect of chemotherapy, yet up to 50% of patients are missing out on vital foot care that could significantly ease their symptoms, according to new research from ...

New imaging probe helps track prostate cancer and possibly treat it before resistance develops

Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a chemical imaging probe that resists the breakdown of certain compounds in the body, giving doctors a more dependable way ...

Depression risk higher among long-term breast cancer survivors than women without breast cancer history

Long-term breast cancer survivors have a higher risk for developing depression, particularly if they have insomnia, according to a study published online Oct. 10 in SLEEPJ.

New study elucidates obesity's role in fueling breast cancer progression

Obesity and cancer are two major health challenges of our time, yet the link between them remains only partially understood. New research now highlights a molecular chain of events in estrogen receptor-positive breast cancer, ...

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

Bacteria are rapidly emerging as a new class of "living medicines" used to kill cancer cells.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

Aerobic and resistance exercise can significantly improve physical performance in patients living with metastatic breast cancer, according to new results presented at the Advanced Breast Cancer Eighth International Consensus ...

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States.

Advanced breast cancer patients living longer thanks to improvements in treatment and care

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the average survival time for patients diagnosed in 2011, according to a major study of patient data in ...

Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects

By analyzing data from three clinical trials treating children with the brain tumor medulloblastoma, scientists at St. Jude Children's Research Hospital have designed an approach to safely reduce therapy, thereby lowering ...

Radiotherapy after mastectomy can be avoided, study finds

Radiotherapy can be safely omitted as a treatment for many breast cancer patients who have had a mastectomy and are taking anti-cancer drugs, a study shows.

Recommended News For You

The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.

The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.

The New Canadian Guidelines for Drinking at High Risk, AUD.

Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.

FDA Expands Durvalumab Label to Operable Lung Cancer

Recommended Articles For You

The Importance of Having a Quick and Effective Heparin Antidote  

Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer 

MMA Embolization in Chronic Subdural Hematoma: Evidence, Outcomes, and Gaps 

The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Predicting adult mortality from oral cancer using a machine learning approach.

2.

Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer

3.

Liver cancer cells under pressure: Compression can spark invasion, drug resistance and altered gene activity

4.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

5.

In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.

1.

Decoding the Failures in Acute Myeloid Leukemia Treatment: Mechanisms, Pathways, & Survival Outcomes

2.

Amivantamab Plus Chemotherapy Outperforms Standard Care in Post-Osimertinib NSCLC

3.

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More

4.

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study

5.

Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

2.

Navigating the Complexities of Ph Negative ALL - Part VI

3.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

4.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot